Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Director departure
Appointed director
CC transcript
CareDx, Inc. (CDNA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "CareDx Reports Second Quarter 2023 Results"
05/10/2023 8-K Quarterly results
Docs: "CareDx Reports First Quarter 2023 Results"
02/27/2023 8-K Investor presentation, Quarterly results
Docs: "CareDx Reports Fourth Quarter and Full Year 2022 Results",
"Q4 2022 9 H1 2022"
11/03/2022 8-K Quarterly results
08/04/2022 8-K Quarterly results
Docs: "CareDx Reports Second Quarter 2022 Results"
05/05/2022 8-K Quarterly results
02/24/2022 8-K Quarterly results
10/28/2021 8-K Quarterly results
Docs: "CareDx Reports Third Quarter 2021 Results Increases Full Year Revenue Guidance"
07/29/2021 8-K Quarterly results
Docs: "CareDx Reports 77% Revenue Growth for Second Quarter of 2021 and Increases Full Year Revenue Guidance"
05/05/2021 8-K Quarterly results
02/24/2021 8-K Quarterly results
10/29/2020 8-K Quarterly results
Docs: "Amendment to Change of Control and Severance Agreement, by and between CareDx, Inc. and Reginald Seeto, MBBS",
"Executive Chair Agreement, by and between CareDx, Inc. and Peter K. Maag, Ph.D",
"CareDx Reports Third Quarter 2020 Results SOUTH SAN FRANCISCO, CA, October 29, 2020 — CareDx, Inc. , a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today reported financial results for the quarter ended September 30, 2020. Third Quarter 2020 and Recent Highlights:",
"Peter Maag Appointed Executive Chairman of the Board of Directors of CareDx; Reginald Seeto Appointed President and CEO SOUTH SAN FRANCISCO, CA, October 29, 2020 — CareDx, Inc. , a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced that effective November 1, 2020, Peter Maag, current Chairman and Chief Executive Officer, will assume the role of Executive Chairman of the Board of Directors, and Reginald Seeto, currently President and Chief Business Officer, will assume the role of President and Chief Executive Officer and will join the CareDx Board of Directors. Peter Maag joined CareDx in 2012 as Chief Executive Officer and has l..."
08/04/2020 8-K Quarterly results
04/30/2020 8-K Quarterly results
Docs: "CareDx Reports First Quarter 2020 Results Strategically positioned for long-term growth and success"
02/27/2020 8-K Quarterly results
10/31/2019 8-K Quarterly results
08/01/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : August 1, 2019 CAREDX, INC. Delaware 001-36536 94-3316839 3260 Bayshore Boulevard Brisbane, California 94005 287-2300 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communi...",
"CareDx Reports Second Quarter 2019 Results"
05/08/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : May 8, 2019 CAREDX, INC. Delaware 001-36536 94-3316839 3260 Bayshore Boulevard Brisbane, California 94005 287-2300 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communicat...",
"CareDx Reports First Quarter 2019 Results"
03/06/2019 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : March 6, 2019 CAREDX, INC. Delaware 001-36536 94-3316839 3260 Bayshore Boulevard Brisbane, California 94005 287-2300 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communic...",
"CareDx Reports Fourth Quarter and FY 2018 Results"
11/08/2018 8-K Quarterly results
Docs: "FORM 8-K",
"CareDx Reports Third Quarter Results"
08/09/2018 8-K Quarterly results
Docs: "UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT PURSUANT TO SECTION 13 OR 15 OF THE SECURITIES EXCHANGE ACT OF 1934 Date of Report : August 9, 2018 CAREDX, INC. Delaware 001-36536 94-3316839 3260 Bayshore Boulevard Brisbane, California 94005 287-2300 Registrant's telephone number, including area code N/A Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐ Written communications pursuant to Rule 425 under the Securities Act ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act ☐ Pre-commencement communications pursuant to Rule 14d-2 under the Exchange Act ) ☐ Pre-commencement communi...",
"CareDx Reports Second Quarter Results"
05/10/2018 8-K Quarterly results
Docs: "FORM 8-K",
"CareDx Reports First Quarter Results"
03/22/2018 8-K Quarterly results
Docs: "CareDx Reports Fourth Quarter and FY2017 Financial Results"
11/09/2017 8-K Quarterly results
Docs: "FORM 8-K",
"CareDx Reports Third Quarter 2017 Financial Results BRISBANE, Calif., November 9, 2017 — CareDx, Inc. , a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the third quarter ended September 30, 2017. Recent highlights:"
08/10/2017 8-K Quarterly results
Docs: "CareDx Reports Second Quarter 2017 Financial Results"
06/09/2017 8-K Quarterly results
Docs: "CareDx Reports First Quarter 2017 Financial Results BRISBANE, Calif., June 9, 2017 — CareDx, Inc. , a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today reported financial results for the first quarter ended March 31, 2017. “We are very pleased with our progress towards AlloSure reimbursement and look forward to soon being able to provide the first and only non-invasive test that uses donor-derived cell free DNA to directly measure organ health and identify the probability of active transplant rejection,” said Peter Maag, CareDx President and Chief Executive Officer. “AlloMap test volume growth has continued, reflecting our reach into the transplant center com..."
04/21/2017 8-K Form 8-K - Current report
11/09/2016 8-K Form 8-K - Current report
08/10/2016 8-K Form 8-K - Current report
05/06/2016 8-K Form 8-K - Current report
03/24/2016 8-K Form 8-K - Current report
11/16/2015 8-K Form 8-K - Current report
08/10/2015 8-K Form 8-K - Current report
05/12/2015 8-K Form 8-K - Current report
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy